JERSEY CITY, N.J., April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovativeanti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April
Title: In Vitro Activity of SCY-078, a Novel IV/Oral Glucan Synthase Inhibitor, against Aspergillus spp., Alone or in Combination with other Antifungal TherapiesPresenter: Mahmoud Ghannoum PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO164Session: Aspergillus in the laboratory
Title: Activity of SCY-078 and comparators against a collection of Aspergillus spp. including cryptic species and Cyp51A mutantsPresenter: Ana Alastruey-Izquierdo PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO165Session: Aspergillus in the laboratory
Title: SCY-078 Demonstrates Antifungal Activity Against Pneumocystis in a Prophylactic Murine Model of Pneumocystis PneumoniaPresenter: Stephen Barat PhDDate and Time: Sunday, April 22, from 13:30-14:30 CETPoster Presentation #: P1226Session: Update on Pneumocystis
The ECCMID 2018 posters will be available on the SCYNEXIS website following the event.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsSusan KimArgot PartnersTel: firstname.lastname@example.org
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: email@example.com
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-disease-eccmid-300625304.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
Necrotizing fasciitis is a rare life threatening bacterial infection of the tissue below the skin ...
Menstruation or period is the discharge of blood and mucus called menses from the uterus via the ...
Chronic dieting is associated with eating disorders that mainly include unhealthy eating practices ...View All